Pamidronate and 1,24(S)-dihydroxyvitamin D2 synergistically inhibit the growth of myeloma, breast and prostate cancer cells

Anticancer Research

Volumn 25, Issue 3 B, 2005, Pages 1909-1917

  Wigington, Don P ^a   Strugnell, S A ^a   Knutson, J C ^a  

^a Bone Care International   (United States)

Author keywords

1,24(OH)2D2; Antiproliferation; Bisphosphonate; Cancer; Vitamin D

Indexed keywords

1,24 DIHYDROXYVITAMIN D2; BISPHOSPHONIC ACID DERIVATIVE; CANCER GROWTH FACTOR; CASPASE; CLODRONIC ACID; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 1; DEXAMETHASONE; DOXERCALCIFEROL; DOXORUBICIN; ERGOCALCIFEROL; GUANINE NUCLEOTIDE BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; PACLITAXEL; PAMIDRONIC ACID; PLATINUM DERIVATIVE; PROTEIN P27; RAS PROTEIN; SEOCALCITOL; TACALCITOL; TAMOXIFEN; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR; ZOLEDRONIC ACID;

APOPTOSIS; ARTICLE; BONE METASTASIS; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CELL ASSAY; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STRAIN; CELL STRAIN H929; CELL STRAIN LNCAP; CELL STRAIN MCF 7; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; HUMAN CELL; HYPERCALCEMIA; IC 50; MITOSIS INHIBITION; MYELOMA; OSTEOLYSIS; PRIORITY JOURNAL; PROSTATE CARCINOMA; TECHNIQUE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ERGOCALCIFEROLS; HUMANS; MALE; MULTIPLE MYELOMA; PROSTATIC NEOPLASMS;

EID: 21344465845     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (75)

1. Yoneda T: Mechanisms of preferential metastasis of breast cancer to bone. Int J Oncol 9: 103-109, 1996.
2. Adami S: Bisphosphonates in prostate carcinoma. Cancer 80: 1674-1679, 1997.
3. Roodman GD: Role of cytokines in the regulation of bone resorption. Calcified Tissue Int 53 Suppl 1: S94-S98, 1993.
4. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, Mariotto A, Fay MP, Feuer EJ and Edwards BK: SEER Cancer Statistics Review, 1975-2000. National Cancer Institute Bethesda, MD 2003.
5. Jung A, Bisaz S, and Fleisch H: The binding of pyrophosphate and two diphoshponates by hydroxyapatite crystals. Calcified Tissue Res 11: 269-280, 1973.
6. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, Mundy GR and Boyce BF: Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Mineral Res 10: 1478-1487, 1995.
7. Hughes DE, MacDonald BR and Russell RGG: Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest 83: 1930-1935, 1989.
8. Vitte C, Fleisch H and Guenther HL: Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinology 137: 2324-2333, 1996.
9. Shipman CM, Rogers MJ, Apperley JF, Russell RGG and Croucher PI: Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol 98: 665-672, 1997.
10. Senaratne SG, Pirianov G, Mansi JL, Arnett TR and Colston KW: Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 82: 1459-1468, 2000.
11. Lee MV, Fong EM, Singer FR and Guenette RS: Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 61: 2602-2608, 2001.
12. Hall DG and Stoica G: Effect of the bisphosphonate risedronate on bone metastases in a rat mammary adenocarcinoma model system. J Bone Mineral Res 9: 221-230, 1994.
13. Sasaki A, Boyce BF and Story B: Bisphosphonate risedronate reduces metastatic human breast cancer burden in nude mice. Cancer Res 55: 3551-3557, 1995.
14. Yoneda T, Michigami T, Yi B, Williams PJ, Niewolna M and Hiraga T: Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma. Cancer 88: 2979-2988, 2000.
15. Hiraga T, Williams PJ, Mundy GR and Yoneda T: The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res 61: 4418-4424, 2001.
16. Pollard M and Luckert PH: Effects of dichloromethylene diphosphonate on the osteolytic and osteoplatic effects of rat prostate adenocarcinoma cells. J Nat Cancer Inst 75: 949-954, 1985.
17. Corey E, Quinn JE, Brown LG, Roudier MPM, Higano C and Vessella RL: Examination of the effects of zoledronic acid on prostate cancer. J Bone Mineral Res 16(Suppl 1): S192, 2001.
18. Croucher PI, De Raeve H and Perry M: Zoldronic acid inhibits the development of osteolytic bone disease and increases survival in a mouse murine model of multiple myeloma. Bone 30: 39S, 2002.
19. Croucher PI, De Hendrik R, Perry MJ, Hijzen A, Shipman CM, Lippitt J, Green J, Van Marck E, Van Camp B and Vanderkerken K: Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Mineral Res 18: 482-492, 2003.
20. Cruz JC, Alsina M and Craig F: Ibadronate decreases bone bone disease development and osteoclast stimulatory activity in an in vivo model of human myeloma. Exp Hematol 29: 441-447, 2001.
21. Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D, Kaufmann M and Bastert G: Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 339: 357-363, 1998.
22. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, Lipton A, Kellar A, Ballester O, Kovacs MJ, Blacklock HA, Bell R, Simeone J, Reitsma DJ, Heffernan M, Seaman J and Knight RD: Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 334: 488-493, 1996.
23. Kanis JA and McCloskey EV: Bisphosphonates in multiple myeloma. Cancer 88: 3022-3032, 2000.
24. Theriault RT, Lipton A, Hortobagyi GN, Leff R, Gluck S, Stewart JF, Costello S, Kennedy I, Simeone J, Seaman J, Knight RD, Mellars K, Heffernan M and Reitsma DJ: Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. J Clin Oncol 17: 846-854, 1999.
25. Saad F, Gleason DM, Murrar R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA and Chen B: A randomized, placebo-controlled, trial of zoledronic acid in patients with hormone-refractory metastatic prostate cancer. J Nat Cancer Inst 94: 1458-1468, 2002.
26. Hortobagyi GN, Theriault RL, Lipton A, Porter L, Blayney D, Sinoff C, Wheeler H, Simeone JF, Seaman JJ, Knight RD, Heffernan M, Mellars K and Reitsma DJ: Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol 16: 2038-2044, 1998.
27. Fleisch H: Bisphosphonates. Pharmacology and use in the treatment of tumor-induced hypercalcemic and metastatic bone disease. Drugs 42: 919-944, 1991.
28. 2 Vitamin D3-regulated expression of the eukaryotic genome. Nutr Rev 52: 376-382, 1994.
29. Holick MF: Noncalcemic actions of 1,25-dihydroxyvitamin D3 and clinical applications. Bone 17: 107S-111S, 1995.
30. Bikle DD and Pillai S: Vitamin D, calcium, and epidermal differentiation. Endocr Rev 14: 3-19, 1993.
31. Evans RM: The steroid and thyroid hormone receptor superfamily. Science 240: 889-895, 1988.
32. Strugnell SA and DeLuca HF: The vitamin D receptor-structure and transcriptional activation. Proc Soc Exp Biol Med 215: 223-228, 1997.
33. Mehta RG and Mehta RR: Vitamin D and cancer. J Nutrit Biochem 13: 252-264, 2002.
34. Park WH, Seol JG, Kim ES, Hyun JM, Jung CW, Lee CC, Binderup L, Koeffler HP, Kim BK and Lee YY: Induction of apoptosis by vitamin D3 analogue EB1089 in NCI-H929 myeloma cells via activation of caspase 3 and p38 MAP kinase. Br J Haematol 109: 576-583, 2000.
35. Mawer EB, Jones G, Davies M, Still PE, Byford V, Schroeder NJ, Makin HLJ, Bishop CW and Knutson JC: Unique 24-hydroxylated metabolites represent a significant pathway of metabolism of vitamin D2 in humans: 24-hydroxyvitamin D2 and 1,24-dihydroxyvitamin D2 detectable in human serum. J Clin Endocrinol Metab 83: 2156-2166, 1998.
36. Jones G, Schnoes HK, LeVan L and DeLuca HF: Isolation and identification of 24-hydroxyvitamin D2 and 24,25-dihydroxyvitamin D2. Arch Biochem Bioph 202: 450-457, 1980.
37. Horst RL, Koszewski NJ and Reinhardt TA: 1α-Hydroxylation of 24-hydroxyvitamin D2 represents a minor physiological pathway for the activation of vitamin D2 in mammals. Biochemistry 29: 578-582, 1990.
38. Strugnell S, Byford V, Makin HLJ, Moriarty RM, Gilardi R, LeVan LW, Knutson JC, Bishop CW and Jones G: 1α,24(S)-Dihydroxyvitamin D2: a biologically active product of 1α-hydroxyvitamin D2 made in the human hepatoma, Hep3B. Biochem J 310: 233-241, 1995.
39. Bauer JA, Thompson TA, Church DR, Ariazi EA and Wilding G: Growth inhibition and differentiation in human prostate carcinoma cells induced by the vitamin D analog 1alpha,24-dihydroxyvitamin D2. Prostate 55: 159-167, 2003.
40. Wigington DP, Urben CM, Strugnell SA and Knutson JC: Combination study of 1,24(S)-Dihydroxyvitamin D2 and chemotherapeutic agents on human breast an prostate cancer cell lines. Anticancer Res 24: 2905-2912, 2004.
41. Levy Y, Knutson JC, Bishop C and Shany S: The novel analog 1,24(S)-dihydroxyvitamin D2 is as equipotent as 1,25-dihydroxyvitamin D3 in growth regulation of cancer cell lines. Anticancer Res 18: 1769-1776, 1998.
42. Shany S, Levy Y and LahavCohen M: The effects of 1 alpha,24(S)- dihydroxyvitamin D-2 analog on cancer cell proliferation and cytokine expression. Steroids 66: 319-325, 2001.
43. Knutson JC, LeVan LW, Valliere CR and Bishop CW: Pharmacokinetics and systemic effect on calcium homeostasis of 1 alpha,24-dihydroxyvitamin D2 in rats. Comparison with 1 alpha,25-dihydroxyvitamin D2, calcitriol, and calcipotriol. Biochem Pharmacol 53: 829-837, 1997.
44. 2 significantly inhibits the growth of MCF-7 tumor xenografts in nude mice. 12TH Workshop on Vitamin D, Abstracts, Maastricht, The Netherlands, pp. 90, 2003.
45. Jagdev SP, Coleman RE, Shipman CM, Rostami H and Croucher PI: The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 84: 1126-1134, 2001.
46. Jagdev SP, Croucher PI and Coleman RE: Zoledronate acid induces apoptosis of breast cancer cells in vitro-evidence for additive and synergistic effects with taxol and tamofifen. Proc Am Soc Clin Oncol 19: 664a, 2000.
47. Tassone P, Forciniti S, Martinelli V, Tagliaferri P and Venuta S: Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines. Leukemia 14: 841-844, 2000.
48. Stearns ME and Wang M: Effects of aledronate and taxol PC-3 ML cell bone metastases in SCID mice. Invasion Metastases 16: 116-131, 1996.
49. Diel IJ, Solomayer EE, Costa SD, Gollan C, Goerner R, Wallwiener D, Kaufmann M and Bastert G: Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 339: 357-363, 1998.
50. Cho YL, Christensen C, Saunders DE, Lawrence WD, Deppe G, Malviya VK, and Malone JM: Combined effects of 1,25-dihydroxyvitamin D3 and platinum drugs on the growth of MCF-7 cells. Cancer Res 51: 2848-2853, 1991.
51. Moffatt KA, Johannes WU and Miller GJ: 1alpha,25Dihydroxyvitamin D3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines. Clin Cancer Res 5: 695-703, 1999.
52. Hershberger PA, McGuire TF, Yu WD, Zuhowski EG, Schellens JH, Egorin MJ, Trump DL and Johnson CS: Cisplatin potentiates 1,25-dihydroxyvitamin D-3-induced apoptosis in association with increased mitogen-activated protein kinase kinase kinase 1 (MEKK-I) expression. Mol Cancer Ther 1: 821-829, 2002.
53. Ravid A, Rocker D, Machlenkin A, Rotem C, Hochman A, Kessler-Icekson G, Liberman UA and Koren R: 1,25-Dihydroxyvitamin D3 enhances the susceptibility of breast cancer cells to doxorubicin-induced oxidative damage. Cancer Res 59: 862-867, 1999.
54. Sundaram S, Chaudhry M, Reardon D, Gupta M and Gewirtz DA: The vitamin D-3 analog EB 1089 enhances the antiproliferative and apoptotic effects of adriamycin in MCF-7 breast tumor cells. Breast Cancer Res Treat 63: 1-10, 2000.
55. Hershberger PA, Yu WD, Modzelewski RA, Rueger RM, Johnson CS and Trump DL: Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel- induced apoptosis. Clin Cancer Res 7: 1043-1051, 2001.
56. Beer TM, Hough KM, Garzotto M, Lowe BA and Henner WD: Weekly high-dose calcitriol and docetaxel in advanced prostate cancer. Semin Oncol 28: 49-55, 2001.
57. Muindi JR, Peng Y, Potter DM, Hershberger PA, Tauch JS, Capozzoli MJ, Egorin MJ, Johnson CS and Trump DL: Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel. Clin Pharmacol Ther 72: 648-659, 2002.
58. Imseis RE, Palmieri GMA, Holbert JM, Leventhal MR and Sebes JI: Effect of calcitriol and pamidronate in multiple myeloma. Am J Medical Sci 318: 61-66, 1999.
59. Chou TC and Talalay P: Analysis of combined drug effects: a new look at a very old problem. Trends Pharmacol Sci 4: 450-454, 1983.
60. Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Reg 22: 27-55, 1984.
61. Chou J and Chou TC: Computerized simulation of dose reduction index (DRI) in synergistic drug combinations. Pharmacologist 30: 231, 1988.
62. Berenbaum MC: What is synergy? Pharmacol Rev 41: 93-141, 1989.
63. Gessner PK: A straightforward method for the study of drug interactions: an isobolographic analysis primer. J Am Coll Toxicol 7: 987-1012, 1988.
64. Church MW, Dintcheff BA and Gessner PK: The interactive effects of alcohol and cocaine on maternal and fetal toxicity in the Long-Evans rat. Neurotoxicol Teratol 10: 355-361, 1988.
65. Santini D, Gentilucci UV, Vincenzi B, Picardi A, Vasaturo F, La Cesa A, Onori N, Scarpa S and Tonini G: The antineoplastic role of bisphosphonates: from basic research to clinical evidence. Ann Oncol 14: 1468-1476, 2003.
66. Smith DC, Johnson CS, Freeman CC, Muindi J, Wilson JW and Trump DL: A Phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy. Clin Cancer Res 5: 1339-1345, 1999.
67. Oiso Y, Tomita A, Hasegawa H, Ariyoshi Y, Niinomi M, Yamamoto M, Takano T and Sakiyama N: Pamidronate treatment in patients with tumor-associated hypercalcemia: pharmaclogical effects and phamacokenetics. Endocrinology 41: 655-661, 1994.
68. Berenson JR, Rosen L, Vescio R, Lau HS, Woo M, Sioufi A, Kowalski MO, Knight RD and Seaman J: Pharmacokenetics of pamidronate disodium in patients with cancer with normal or impaired renal function. J Clin Pharmacol 37: 285-290, 1997.
69. Zhuang SH and Burnstein KL: Antiproliferative effect of 1α,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. Endocrinology 139: 1197-1207, 1998.
70. 3 on the cell cycle genes, cyclin D1, p21 and p27 in MCF-7 cells. Mol Cell Endocrinol 142: 57-65, 1998.
71. Park WH, Seol JG, Kim ES, Binderup L, Koeffler HP, Kim BK and Lee YY: The induction of apoptosis by a combined 1,25(OH)(2)D-3 analog, EB1089 and TGF-beta 1 in NCI-H929 multiple myeloma cells. Int J Oncol 20: 533-542, 2002.
72. McGuire TF, Trump DL and Johnson CS: Vitamin D-3-induced apoptosis of murine squamous cell carcinoma cells - selective induction of caspase-dependent MEK cleavage and up-regulation of MEKK-1. J Biol Chem 276: 26365-26373, 2001.
73. Senaratne SG, Mansi JL and Colston KW: The bisphosphonate zoledronic acid impairs Ras membrane [correction of impairs membrane] localisation and induces cytochrome c release in breast cancer cells. Br J Cancer 86: 1479-1486, 2002.
74. Oades GM, Senaratne SG, Clarke IA, Kirby RS and Colston KW: Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells. J Urol 170: 246-252, 2003.
75. Tassone P, Tagliaferri P, Viscomi C, Palmieri C, Caraglia M, D'Alessandro A, Galea E, Goel A, Abbruzzese A, Boland CR and Venuta S: Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro. Br J Cancer 12: 1971-1978, 2003.